https://www.onclive.com/view/dana-farber-launches-new-platform-to-bring-its-cancer-treatment-expertise-directly-to-oncologists-clinical-workflow2026-09-14T16:00:00Z2026-09-14T16:00:00Z https://www.onclive.com/view/fda-withdraws-indication-for-adagrasib-plus-cetuximab-in-previously-treated-kras-g12c-mutated-mcrc2026-09-14T15:30:00Z2026-09-14T15:30:00Z https://www.onclive.com/view/fda-reduces-monitoring-time-for-first-two-doses-of-tarlatamab-es-sclc2026-09-14T14:44:57.616Z2026-09-14T14:44:57.616Z https://www.onclive.com/view/fda-approves-tlx101-px-for-glioma-imaging2026-09-14T14:00:11.084Z2026-09-14T14:00:11.084Z https://www.onclive.com/view/fda-approves-aminolevulinic-acid-hydrochloride-plus-pdt-for-basal-cell-carcinoma2026-09-14T13:44:21.123Z2026-09-14T13:44:21.123Z https://www.onclive.com/view/post-progression-management-resistance-mechanisms-and-future-directions-in-egfr-mutated-nsclc2026-09-14T12:35:00Z2026-09-14T12:35:00Z https://www.onclive.com/view/local-consolidative-therapy-oligoprogression-management-and-regimen-selection-in-egfr-mutated-nsclc2026-09-14T12:30:00Z2026-09-14T12:30:00Z https://www.onclive.com/view/clinical-scenario-2-frontline-treatment-selection-for-metastatic-egfr-mutated-nsclc-with-cns-metastases2026-09-14T12:25:00Z2026-09-14T12:25:00Z https://www.onclive.com/view/expanding-adjuvant-targeted-therapy-beyond-egfr-and-the-promise-of-neoadjuvant-approaches-in-nsclc2026-09-14T12:20:00Z2026-09-14T12:20:00Z https://www.onclive.com/view/adaura-8-year-overall-survival-data-and-stage-specific-implications-for-adjuvant-therapy-in-egfr-mutated-nsclc2026-09-14T12:15:00Z2026-09-14T12:15:00Z https://www.onclive.com/view/managing-osimertinib-toxicity-and-treatment-adherence-in-adjuvant-egfr-mutated-nsclc2026-09-14T12:10:00Z2026-09-14T12:10:00Z https://www.onclive.com/view/adaura-in-clinical-practice-treatment-duration-adherence-and-shared-decision-making-in-egfr-mutated-nsclc2026-09-14T12:05:00.000Z2026-09-14T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-preparing-patients-for-the-car-t-cell-therapy-journey2026-09-14T12:05:00Z2026-09-14T12:05:00Z https://www.onclive.com/view/sequencing-therapy-after-bcma-directed-car-t-and-bispecific-antibodies-in-multiple-myeloma2026-09-14T12:05:00Z2026-09-14T12:05:00Z https://www.onclive.com/view/tki-based-therapy-is-associated-with-improved-disease-control-in-metastatic-translocation-rcc2026-09-14T12:00:00Z2026-09-14T12:00:00Z https://www.onclive.com/view/adjuvant-treatment-paradigm-in-resected-egfr-mutated-nsclc-setting-the-stage-with-clinical-scenario-12026-09-14T12:00:00.000Z2026-09-14T12:00:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-shared-decision-making-and-treatment-goals2026-09-14T12:00:00Z2026-09-14T12:00:00Z https://www.onclive.com/view/quadruplet-therapy-and-treatment-individualization-in-newly-diagnosed-multiple-myeloma2026-09-14T12:00:00Z2026-09-14T12:00:00Z https://www.onclive.com/view/comprehensive-ngs-becomes-gateway-perioperative-targeted-therapy-nsclc-qa-jay-m-lee-md2026-09-14T09:25:00Z2026-09-14T09:25:00Z https://www.onclive.com/view/neoadjuvant-alectinib-moves-the-best-systemic-therapy-up-front-in-resectable-alk-nsclc-a-qa-with-jay-m-lee-md2026-09-14T09:15:00Z2026-09-14T09:15:00Z https://www.onclive.com/view/dr-gandara-on-expanding-beyond-pd-l1-as-a-biomarker-in-nsclc2026-09-14T08:40:32.962Z2026-09-14T08:40:32.962Z https://www.onclive.com/view/dr-gandara-on-the-kras-g12c-survival-signal-with-cemiplimab-in-empower-lung-12026-09-14T05:22:51.802Z2026-09-14T05:22:51.802Z https://www.onclive.com/view/frontline-amivantamab-chemotherapy-34-3-month-median-os-egfr-exon-20-insertion-nsclc-papillon2026-09-14T03:00:00Z2026-09-14T03:00:00Z https://www.onclive.com/view/adjuvant-osimertinib-keeps-os-benefit-8-years-resected-egfr-mutated-stage-ib-to-iiia-nsclc2026-09-14T02:24:31.895Z2026-09-14T02:24:31.895Z https://www.onclive.com/view/zidesamtinib-yields-high-response-rates-in-tki-naive-advanced-ros1-nsclc2026-09-14T01:43:07.735Z2026-09-14T01:43:07.735Z https://www.onclive.com/view/destiny-lung04-showcases-pfs-benefit-with-first-line-t-dxd-in-her2-mutant-nsclc2026-09-14T01:20:19.309Z2026-09-14T01:20:19.309Z https://www.onclive.com/view/dr-raez-on-oral-options-reshaping-ros1-her2-mutant-and-egfr-exon-20-nsclc2026-09-14T01:00:00Z2026-09-14T01:00:00Z https://www.onclive.com/view/dr-santos-castillero-on-maverick-b7-h3-adcs-and-the-shifting-sclc-landscape2026-09-14T00:16:02.606Z2026-09-14T00:16:02.606Z https://www.onclive.com/view/dr-veluswamy-on-the-emergence-of-kras-g12c-inhibitors-in-nsclc2026-09-13T22:18:42.283Z2026-09-13T22:18:42.283Z https://www.onclive.com/view/dr-raez-on-improving-access-screening-amid-lung-cancer-treatment-boom2026-09-13T22:09:41.586Z2026-09-13T22:09:41.586Z https://www.onclive.com/view/intercalated-gefitinib-plus-chemotherapy-improves-dfs-in-resected-egfr-mutant-nsclc2026-09-13T10:15:00Z2026-09-13T10:15:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-9-62026-09-13T10:00:00Z2026-09-13T10:00:00Z https://www.onclive.com/view/dr-spira-on-the-data-supporting-the-phase-3-development-of-iza-bren-in-egfr-mutant-nsclc2026-09-13T06:19:00Z2026-09-13T06:19:00Z https://www.onclive.com/view/early-discontinuation-of-adjuvant-osimertinib-doubles-recurrence-risk-in-egfr-mutated-nsclc2026-09-13T04:48:00Z2026-09-13T04:48:00Z https://www.onclive.com/view/ris-rez-extends-median-os-months-vs-topotecan-relapsed-sclc2026-09-13T03:34:50.010Z2026-09-13T03:34:50.010Z https://www.onclive.com/view/tam-peli-reduces-risk-death-vs-topotecan-relapsed-sclc2026-09-13T03:09:07.494Z2026-09-13T03:09:07.494Z https://www.onclive.com/view/dr-liu-on-building-on-the-adriatic-regimen-in-limited-stage-small-cell-lung-cancer2026-09-12T12:23:00.000Z2026-09-12T21:45:00Z https://www.onclive.com/view/dr-felip-on-sequencing-next-generation-ros1-tkis-after-progression-in-nsclc2026-09-12T21:30:00Z2026-09-12T21:30:00Z https://www.onclive.com/view/dr-paz-ares-on-managing-the-toxicities-associated-with-newer-therapies-in-sclc2026-09-12T10:15:00.000Z2026-09-12T21:15:00Z https://www.onclive.com/view/iza-bren-orr-pfs-post-osimertinib-egfr-mutated-nsclc2026-09-12T21:00:00Z2026-09-12T21:00:00Z https://www.onclive.com/view/dr-mitsudomi-on-managing-uncommon-egfr-mutations-compared-with-classical-exon-19-21-alterations-in-nsclc2026-09-12T21:00:00Z2026-09-12T21:00:00Z https://www.onclive.com/view/dr-xia-on-common-resistance-mechanisms-in-nsclc-following-egfr-tki-failure2026-09-12T20:40:00Z2026-09-12T20:40:00Z https://www.onclive.com/view/perioperative-atezolizumab-plus-chemotherapy-extends-efs-resectable-nsclc2026-09-12T20:33:27.528Z2026-09-12T20:33:27.528Z https://www.onclive.com/view/dr-li-on-the-decision-between-her2-directed-tkis-and-adcs-in-frontline-nsclc2026-09-12T20:25:00Z2026-09-12T20:25:00Z https://www.onclive.com/view/pumitamig-elfetabart-drozuntecan-orr-sclc2026-09-12T10:45:00Z2026-09-12T10:45:00Z https://www.onclive.com/view/extended-interval-tarlatamab-exposure-survival-q2w-dose-previously-treated-sclc2026-09-12T10:15:00Z2026-09-12T10:15:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-9-62026-09-12T10:00:00Z2026-09-12T10:00:00Z https://www.onclive.com/view/subcutaneous-tarlatamab-safe-active-against-es-sclc-tumors-phase-1b-es-sclc-trial2026-09-12T09:45:00Z2026-09-12T09:45:00Z https://www.onclive.com/view/lct-after-nivolumab-ipilimumab-induction-fails-improve-metastatic-nsclc-survival2026-09-12T09:15:00Z2026-09-12T09:15:00Z https://www.onclive.com/view/dr-grant-on-the-unanswered-questions-in-perioperative-nsclc2026-09-12T08:00:00Z2026-09-12T08:00:00Z https://www.onclive.com/view/advice-early-career-oncologists-wclc-20262026-09-12T06:52:25.741Z2026-09-12T06:52:25.741Z https://www.onclive.com/view/serena-4-misses-primary-pfs-end-point-with-camizestrant-plus-palbociclib-in-first-line-er-advanced-breast-cancer2026-09-12T00:00:00Z2026-09-12T00:00:00Z https://www.onclive.com/view/dibotatug-is-safe-and-yields-durable-responses-in-large-granular-lymphocytic-leukemia2026-09-11T21:55:00Z2026-09-11T21:55:00Z https://www.onclive.com/view/asciminib-maintains-superior-mmr-and-favorable-safety-at-3-years-in-newly-diagnosed-ph-cml2026-09-11T21:15:00Z2026-09-11T21:15:00Z https://www.onclive.com/view/fda-extends-review-period-for-zanzalintinib-plus-atezolizumab-nda-in-pretreated-mcrc2026-09-11T21:04:11.085Z2026-09-11T21:04:11.085Z https://www.onclive.com/view/prophylactic-tocilizumab-reduces-crs-in-outpatient-teclistamab-talquetamab-myeloma2026-09-11T20:33:45.791Z2026-09-11T20:33:45.791Z https://www.onclive.com/view/rusfertide-maintains-clinical-response-hematocrit-control-across-risk-groups-in-pv2026-09-11T19:54:50.836Z2026-09-11T19:54:50.836Z https://www.onclive.com/view/dr-bose-on-the-potential-role-of-selinexor-plus-ruxolitinib-in-myelofibrosis2026-09-11T19:45:18.437Z2026-09-11T19:45:18.437Z https://www.onclive.com/view/the-adc-revolution-in-metastatic-breast-cancer-redefining-treatment-selection-and-sequencing2026-09-11T17:56:17.975Z2026-09-11T17:56:17.975Z https://www.onclive.com/view/dr-gangat-on-efficacy-data-for-selcodebart-in-myelofibrosis-associated-anemia2026-09-11T16:53:13.247Z2026-09-11T16:53:13.247Z https://www.onclive.com/view/time-limited-pirtobrutinib-based-triplet-yields-high-rates-of-undetectable-mrd-in-first-line-cll2026-09-11T16:35:00Z2026-09-11T16:35:00Z https://www.onclive.com/view/roswell-park-breaks-ground-on-expanded-roswell-park-broadview-community-outreach-and-engagement-center2026-09-11T16:00:00Z2026-09-11T16:00:00Z https://www.onclive.com/view/anselamimab-misses-overall-primary-end-point-but-reduces-mortality-in-kappa-al-amyloidosis2026-09-11T15:00:04.904Z2026-09-11T15:00:04.904Z https://www.onclive.com/view/onclive-weekly-news-quiz-9-11-20262026-09-11T13:16:09.573Z2026-09-11T13:16:09.573Z https://www.onclive.com/view/individualizing-first-line-checkpoint-inhibitor-selection-in-an-older-comorbid-patient2026-09-11T12:05:00Z2026-09-11T12:05:00Z https://www.onclive.com/view/fda-approval-of-daraxonrasib-in-pancreatic-cancer2026-09-11T12:02:00Z2026-09-11T12:02:00Z https://www.onclive.com/view/kras-alleles-and-genomic-testing-in-pancreatic-cancer2026-09-11T12:01:00Z2026-09-11T12:01:00Z https://www.onclive.com/view/kras-biology-and-molecular-profiling-in-pancreatic-cancer2026-09-11T12:00:00Z2026-09-11T12:00:00Z https://www.onclive.com/view/case-presentation-a-79-year-old-woman-with-unresectable-cutaneous-squamous-cell-carcinoma2026-09-11T12:00:00Z2026-09-11T12:00:00Z https://www.onclive.com/view/dr-sallman-on-next-steps-for-ofirnoflast-in-lower-risk-mds2026-09-10T21:35:17.704Z2026-09-10T21:35:17.704Z https://www.onclive.com/view/elvn-001-produces-molecular-responses-in-heavily-pretreated-cp-cml2026-09-10T21:15:00Z2026-09-10T21:15:00Z https://www.onclive.com/view/active-regimen-elicits-high-response-rates-in-r-r-npm1-mutated-aml2026-09-10T19:50:00Z2026-09-10T19:50:00Z https://www.onclive.com/view/revumenib-plus-chemo-yields-high-response-and-mrd-negativity-rates-in-newly-diagnosed-npm1-or-kmt2a-aml2026-09-10T19:25:10.717Z2026-09-10T19:25:10.717Z https://www.onclive.com/view/dr-gangat-on-phase-2-efficacy-and-safety-data-for-disc-3405-in-polycythemia-vera2026-09-10T19:17:57.450Z2026-09-10T19:17:57.450Z https://www.onclive.com/view/reassessing-the-continuous-vs-fixed-duration-debate-in-frontline-chronic-lymphocytic-leukemia2026-09-10T18:00:00Z2026-09-10T18:00:00Z https://www.onclive.com/view/unmet-needs-in-allogeneic-transplant-and-precision-t-data-discussion2026-09-10T17:00:00Z2026-09-10T17:00:00Z https://www.onclive.com/view/ofirnoflast-elicits-durable-transfusion-independence-hematologic-improvement-in-lower-risk-mds2026-09-10T16:44:14.266Z2026-09-10T16:44:14.266Z https://www.onclive.com/view/systemic-therapy-for-advanced-cutaneous-squamous-cell-carcinoma-evidence-and-clinical-decision-making2026-09-10T16:33:26.988Z2026-09-10T16:33:26.988Z https://www.onclive.com/view/mayo-clinic-researchers-find-a-way-to-reprogram-immune-cells-and-boost-chemotherapy-response-in-glioblastoma2026-09-10T16:00:00Z2026-09-10T16:00:00Z https://www.onclive.com/view/disc-3405-reduces-phlebotomy-events-and-controls-hematocrit-in-polycythemia-vera2026-09-10T15:31:13.400Z2026-09-10T15:31:13.400Z https://www.onclive.com/view/selcodebart-yields-hematologic-responses-and-reduces-transfusion-burden-in-myelofibrosis-related-anemia2026-09-10T15:10:15.968Z2026-09-10T15:10:15.968Z https://www.onclive.com/view/differentiation-between-proliferative-and-cytopenic-disease-could-aid-treatment-selection-in-myelofibrosis2026-09-10T14:00:00Z2026-09-10T14:00:00Z https://www.onclive.com/view/how-compassion-and-research-build-palliative-care-for-the-precision-oncology-era2026-09-09T20:55:00Z2026-09-09T20:55:00Z https://www.onclive.com/view/tkd-mutation-status-and-cns-data-guide-frontline-sequencing-in-her2-mutant-nsclc2026-09-09T17:45:00Z2026-09-09T17:45:00Z https://www.onclive.com/view/namodenoson-generates-longer-than-anticipated-os-advanced-hcc2026-09-09T17:15:00Z2026-09-09T17:15:00Z https://www.onclive.com/view/micvotabart-pelidotin-monotherapy-yields-responses-in-pretreated-recurrent-metastatic-hnscc2026-09-09T16:51:47.776Z2026-09-09T16:51:47.776Z https://www.onclive.com/view/new-surgery-offers-new-treatment-options-for-patients-with-advanced-abdominal-cancers2026-09-09T16:00:00Z2026-09-09T16:00:00Z https://www.onclive.com/view/fda-approves-sevabertinib-for-advanced-her2-tkd-mutated-nonsquamous-nsclc2026-09-09T15:46:33.089Z2026-09-09T15:46:33.089Z https://www.onclive.com/view/dabogratinib-elicits-responses-in-fgfr3-low-grade-intermediate-risk-nmibc2026-09-09T13:53:08.597Z2026-09-09T13:53:08.597Z https://www.onclive.com/view/patient-selection-for-frontline-multiple-myeloma-therapy2026-09-09T12:05:00Z2026-09-09T12:05:00Z https://www.onclive.com/view/frontline-multiple-myeloma-management2026-09-09T12:00:00Z2026-09-09T12:00:00Z https://www.onclive.com/view/frontline-mipletamig-triplet-drives-clinical-benefit-in-tp53-mutated-aml2026-09-08T16:18:31.768Z2026-09-08T16:18:31.768Z https://www.onclive.com/view/ai-may-help-identify-breast-cancers-missed-by-mammograms-but-clinical-benefit-remains-uncertain2026-09-08T16:00:00Z2026-09-08T16:00:00Z https://www.onclive.com/view/durvalumab-plus-tarlatamab-boosts-survival-as-first-line-es-sclc-maintenance2026-09-08T15:43:41.450Z2026-09-08T15:43:41.450Z https://www.onclive.com/view/real-world-data-highlight-prognostic-value-of-ctdna-testing-in-lymphomas2026-09-08T15:21:40.683Z2026-09-08T15:21:40.683Z https://www.onclive.com/view/camidge-and-singhi-highlight-the-lung-cancer-abstracts-to-watch-at-wclc-20262026-09-08T15:00:00Z2026-09-08T15:00:00Z https://www.onclive.com/view/comprehensive-assessment-for-car-t-cell-therapy-in-large-b-cell-lymphoma2026-09-08T12:05:00Z2026-09-08T12:05:00Z https://www.onclive.com/view/arlo-cel-meets-orr-end-point-in-bcma-pretreated-quadruple-class-exposed-r-r-myeloma2026-09-08T12:00:00Z2026-09-08T12:00:00Z https://www.onclive.com/view/comorbidities-and-patient-selection-for-car-t-cell-therapy-in-large-b-cell-lymphoma2026-09-08T12:00:00Z2026-09-08T12:00:00Z https://www.onclive.com/view/linvoseltamab-improves-health-related-quality-of-life-in-relapsed-refractory-multiple-myeloma2026-09-07T13:00:00Z2026-09-07T13:00:00Z